Brand and Other Names:Ardovax
- Classes: Vaccines, Live, Viral
Dosing & Uses
Dosage Forms & Strengths
- Adenovirus type 4≥4.5 log10 TCID50
- Adenovirus tyep 7≥4.5 log10 TCID50
Adenovirus Active Immunization
Indicated for active immunization of military populations for prevention of febrile acute respiratory disease caused by adenovirus types 4 and 7
Aged 17-50 years: Single vaccine dose consists of 2 tablets: 1 tablet of adenovirus type 4 and one tablet of adenovirus type 7
Swallow tablets whole, do not chew, crush, or split; chewing a tablet could expose the upper respiratory tract to live adenovirus leading to disease
- Refrigerate between 2-8 degrees C (35-46 degrees F); protect from moisture; do not remove desiccant from bottle
<17 years: Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Adverse effects were similar to placebo for the first 7 days following vaccination; those listed below were slightly higher than those for placebo
Nasal congestion (15.3%)
Limb pain (4%)
Inability to swallow table whole (chewing a tablet could expose the upper respiratory tract to live adenovirus leading to disease)
Vomiting or diarrhea could decrease effectiveness of vaccine
Safety has not been evaluated in individuals with altered immunocompetence
Contains live viruses that are shed in the stool and can cause disease if transmitted; those vaccinated should avoid close contact with children younger than 7 years and immunocompromised individuals
Tablets contain human albumin (<0.3 mg/tablet), which could theortetically increase risk transmission of blood borne diseases (e.g., Creuzfeldt-Jakob disease)
Effective immunity may not occur in all vaccinated patients
Pregnancy & Lactation
Pregnancy Category: X
Unknown whether adenovirus can cause fetal harm; naturally occurring infection with adenoviruses has been associated with fetal harm
Lactation: Unknown whether distributed in breast milk; caution advised
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Live oral vaccine that replicates in intestinal tract and induces immunity in persons with low or no pre-existing neutralizing antibodies to adenoviruses types 4 and 7
Duration: Viral shedding not detected after 28 days
Onset: Viral shedding in the stool starts at 7 days; seroconversion starts at 26 days following vaccination
Absorption: Not detected in serum (limited data)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs